Everything below concerns Nucleotide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-12. Numbers and descriptions here follow the published literature rather than marketing material.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Nucleotide intermediate in NAD+ salvage pathway |
| Common abbreviation | NMN | Also written as β-NMN |
| Molecular formula | C11H15N2O8P | Uncharged parent form |
| Molar mass | 334.22 g/mol | Calculated from formula |
| CAS Registry Number | 1094-61-7 | For β-nicotinamide mononucleotide |
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
== Description == The cap of this mushroom grows up to 8–30 cm (3–12 in) wide, sometimes more. Viscid when moist, the cap is convex when young and flattens with age. The colour is generally reddish-brown, sometimes with a paler margin. The stipe grows up to 8–25 cm (3–10 in) tall and 2–7 cm (1–3 in) thick—rather large in comparison to the cap. The stem is usually enlarged at the base when young, becoming more cylindrical in age. It is finely reticulate on the upper portion or sometimes the whole. The flesh of the stem is sometimes dark yellow near the base. The undersurface of the cap consists of thin tubes, the site of spore production; they are 1 to 2 cm (1⁄2 to 3⁄4 in) deep, and whitish in colour when young, but mature to a greenish-yellow. The angular pores, which do not stain when bruised, are small—roughly 2 to 3 pores per millimetre. In youth, the pores are white and appear as if stuffed with cotton (which are actually mycelia); as they age, they change colour to yellow and later to brown. The spore print is olive brown. The flesh of the fruit body is white, thick and firm when young, but becomes somewhat spongy with age. When bruised or cut, it either does not change colour, or turns a very light brown or light red. Mature specimens can weigh about 1 kg (2 lb 3 oz). A huge specimen collected on the Isle of Skye, Scotland, in 1995 weighed 3.2 kg (7 lb 1 oz); its cap was 42 cm (16+1⁄2 in) wide and the stipe was 18 cm (7 in) tall and 14 cm (5+1⁄2 in) wide. A similarly sized specimen found in Poland in 2013 made international news.
==== 1.B. β-Barrel porins and other outer membrane proteins ==== 1.B.1 General bacterial porin family 1.B.2 Chlamydial porin (CP) family 1.B.3 Sugar porin (SP) family 1.B.4 Brucella-Rhizobium porin (BRP) family 1.B.5 Pseudomonas OprP porin (POP) family 1.B.6 OmpA-OmpF porin (OOP) family 1.B.7 Rhodobacter PorCa porin (RPP) family 1.B.8 Mitochondrial and plastid porin (MPP) family 1.B.9 FadL outer membrane protein (FadL) family 1.B.10 Nucleoside-specific channel-forming outer membrane porin (Tsx) family 1.B.11 Outer membrane fimbrial usher porin (FUP) family 1.B.12 Autotransporter-1 (AT-1) family 1.B.13 Alginate export porin (AEP) family 1.B.14 Outer membrane receptor (OMR) family 1.B.15 Raffinose porin (RafY) family 1.B.16 Short chain amide and urea porin (SAP) family 1.B.17 Outer membrane factor (OMF) family 1.B.18 Outer membrane auxiliary (OMA) protein family 1.B.19 Glucose-selective OprB porin (OprB) family 1.B.20 Two-partner secretion (TPS) family 1.B.21 OmpG porin (OmpG) family 1.B.22 Outer bacterial membrane secretin (secretin) family 1.B.23 Cyanobacterial porin (CBP) family 1.B.24 Mycobacterial porin 1.B.25 Outer membrane porin (Opr) family 1.B.26 Cyclodextrin porin (CDP) family 1.B.31 Campylobacter jejuni major outer membrane porin (MomP) family 1.B.32 Fusobacterial outer membrane porin (FomP) family 1.B.33 Outer membrane protein insertion porin (Bam complex) (OmpIP) family 1.B.34 Corynebacterial porins 1.B.35 Oligogalacturonate-specific porin (KdgM) family 1.B.39 Bacterial porin, OmpW (OmpW) family 1.B.42 Outer membrane lipopolysaccharide export porin (LPS-EP) family 1.B.43 Coxiella porin P1 (CPP1) family 1.B.44 Probable protein translocating porphyromonas gingivalis porin (PorT) family 1.B.49 Anaplasma P44 (A-P44) porin family 1.B.48 Curli-like transporters 1.B.54 Intimin/Invasin (Int/Inv) or Autotransporter-3 family 1.B.55 Poly-acetyl-D-glucosamine porin (PgaA) family 1.B.57 Legionella major-outer membrane protein (LM-OMP) family 1.B.60 Omp50 porin (Omp50 Porin) family 1.B.61 Delta-proteobacterial porin (Delta-porin) family 1.B.62 Putative bacterial porin (PBP) family 1.B.66 Putative beta-barrel porin-2 (BBP2) family 1.B.67 Putative beta barrel porin-4 (BBP4) family 1.B.68 Putative beta barrel porin-5 (BBP5) superfamily 1.B.70 Outer membrane channel (OMC) family 1.B.71 Proteobacterial/verrucomicrobial porin (PVP) family 1.B.72 Protochlamydial outer membrane porin (PomS/T) family 1.B.73 Capsule biogenesis/assembly (CBA) family 1.B.78 DUF3374 electron transport-associated porin (ETPorin) family
In 1867, the Austro-Hungarian compromise and the introduction of the dual monarchy left the Czechs and their aristocracy without the recognition of separate Bohemian state rights for which they had hoped. Bohemia remained part of the Austrian Crown Lands. In Bohemia, opposition to dualism took the form of isolated street demonstrations, resolutions from district representations, and even open air mass protest meetings, confined to the biggest cities, such as Prague. The Czech newspaper Národní listy complained that the Czechs had not yet been compensated for their wartime losses and sufferings during the Austro-Prussian War, and had just seen their historic state rights tossed aside and their land subsumed into the "other" half of the Austro-Hungarian Monarchy, commonly called "Cisleithania". The Czech hopes were revived again in 1870–1871. In an Imperial Rescript of 26 September 1870, Franz Joseph referred again to the prestige and glory of the Bohemian Crown and to his intention to hold a coronation. Under Minister-President Karl Hohenwart in 1871, the government of Cisleithania negotiated a series of fundamental articles spelling out the relationship of the Bohemian Crown to the rest of the Habsburg Monarchy. On 12 September 1871, Franz Joseph announced:
Sources: en.wikipedia.org
=== Skin pigmentation === Though MCH was initially discovered for its role in determining pigmentation levels in fish, determining MCH's role in mammalian skin pigmentation has been much more difficult. However, MCHR1 has been found in human melanocytes and some melanoma cells, so MCH is able to bind to these cells as well as keratinocytes though they do not express MCHR1. In melanocytes, MCH seems to have an antagonistic relationship with α-MSH, and decreased melanin production. Though, more information is needed to fully understand MCH's relationship with skin pigmentation in mammals.
== Eutectic mixture == Separately, lidocaine and prilocaine are solid bases. When mixed in equal quantities by weight, however, they form a eutectic mixture – that is the melting point of the mixture is lower than the melting points of the individual components. The lidocaine/prilocaine eutectic mixture is an oil with a melting point of 18 °C, and can be formulated into preparations without the use of a non-aqueous solvent. This allows higher concentrations of anaesthetic to be formulated into the preparation and maintained during application.
=== 1982 === February 24: President Ronald Reagan announces the "Caribbean Basin Initiative" to prevent the overthrow of governments in the region by the forces of communism. March 22: President Ronald Reagan signs P.L. 97-157 denouncing the government of the Soviet Union that it should cease its abuses of the basic human rights of its citizens. April 2: Argentina invades the Falkland Islands, starting the Falklands War. May 30: Spain joins NATO. June 6: Israel invades Lebanon to end raids and clashes with Syrian troops based there. June 14: Falkland Islands liberated by British task force. End of the Falklands War. August 1: Rebels attempt to seize control of Kenya, with the supposed assist of the communists in a coup d'état. The coup failed. November 10: Leonid Brezhnev dies from a heart failure with his funeral being held five days later. November 14: Yuri Andropov becomes General Secretary of the Soviet Union.
Sources: en.wikipedia.org
The safe storage of food for home use should strictly adhere to guidelines set out by reliable sources, such as the United States Department of Agriculture or the European Food Safety Authority. Scientists have thoroughly researched these guidelines to determine the most effective methods for reducing the real threat of food poisoning caused by unsafe food storage. It is also important to maintain proper kitchen hygiene to reduce the risk of bacterial or viral growth and food poisoning. The common food poisoning illnesses include Listeriosis, Mycotoxicosis, Salmonellosis, E. coli, Staphylococcal food poisoning and Botulism. Many other organisms can also cause food poisoning. There are also safety guidelines for the correct methods of home canning. For example, there are specific boiling times that apply depending upon whether pressure canning or waterbath canning is being used in the process. These safety guidelines are intended to reduce the growth of mold and bacteria and the threat of potentially fatal food poisoning.
=== Dry co-micronization === Dry co-micronization is a nanomilling approach in which the drug substance is milled in a dry state together with GRAS excipients in a single unit operation. The excipients form a protective dispersion matrix around the sub-micron drug particles, preventing the surface-energy-driven reaggregation that otherwise dominates dry submicron powders, and yielding a free-flowing powder that can be tableted or encapsulated without further drying or downstream processing. The most widely commercialized dry co-micronization platform is SoluMatrix Fine Particle Technology, developed by iCeutica and acquired in 2011 by Iroko Pharmaceuticals. The platform has been used to formulate three U.S. Food and Drug Administration–approved low-dose non-steroidal anti-inflammatory drugs: Zorvolex (diclofenac, approved October 2013), Tivorbex (indomethacin, approved February 2014), and Vivlodex (meloxicam, approved October 2015). Each product was approved at a total daily dose 20–35% below the equivalent conventionally-formulated NSAID, on the basis that the increased dissolution rate of sub-micron particles permits comparable analgesic efficacy at lower systemic exposure. Unlike wet media milling, dry co-micronization requires no aqueous suspension or downstream drying step, shortening the unit-operation chain at the cost of constraining the formulation to excipients compatible with high-energy dry impact.
A study by Columbia University researchers suggests hypermetabolism in cells due to impaired mitochondria is a driver of aging. A previously unknown cell mechanism involved in aging is discovered, which explains how cells 'remember' their identity when they divide – the cells' so-called epigenetic memory. A team of scientists from New York University identifies a potential cause of greying hair with age as the failure of melanocyte stem cells to mature with age. The study was carried out using mice, which have identical cells for their fur. According to the research team, the results could provide a basis for reversing the hair greying process. A study affirms and explains why a moderate decrease in body temperature extends lifespan. A study finds that human organs may age at different rates in some individuals, finding that nearly 20% of the 5,676 adults screened showed signs of accelerated aging in one organ and that 1.7% had more than one organ in a state of accelerated aging. By publishing virome-related results, researchers close a major gap in the acceleratingly accumulating research into centenarians' microbiome characteristics for life extension. Scientists at the University of Colorado report what they believe to be the primary mechanism behind cognitive decline in aging, the mis-regulation of the brain protein CaMKII. Three studies indicate platelets, including or especially FF4, are exerkines with health- and life-extension-potential that rejuvenate aging brains of mice.
Researchers at Bristol-Myers Squibb found that increased steric bulk of the N-terminal amino acid side-chain led to increased stability. To additionally increase stability the trans-rotamer was stabilized with a cis-4,5-methano substitution of the pyrrolidine ring, resulting in an intramolecular van-der-Waals interaction, thus preventing intramolecular cyclisation. Because of that increased stability, the researchers continued their investigation on cis-4,5-methano cyanopyrrolidines and came across with a new adamantyl derivative, which showed extraordinary ex vivo DPP-4 inhibition in rat plasma. Also noted, high microsomal turnover rate which indicated that the derivative was quickly converted to an active metabolite. After hydroxylation on the adamantyl group they had a product with better microsomal stability and improved chemical stability. That product was named saxagliptin (Onglyza) (Figure 6). In June 2008 AstraZeneca and Bristol-Myers Squibb submitted a new drug application for Onglyza in the United States and a marketing authorization application in Europe. Approval was granted in the United States by the FDA in July 2009 for Onglyza 5 mg and Onglyza 2.5 mg. This was later combined with extended-release metformin (taken once daily) and approved by the FDA in January 2011 under the trade name Kombiglyze XR.
Sources: en.wikipedia.org
NMN is nicotinamide mononucleotide, a nucleotide intermediate in the NAD+ salvage pathway. Cells use it to help regenerate NAD+, a coenzyme involved in energy metabolism and cellular signaling. It is present naturally in many organisms and is also produced synthetically for research and consumer products.
NMN is the immediate precursor to NAD+ in the salvage pathway. The enzyme NMN adenylyltransferase adds an adenylate group to NMN to form NAD+. Because NAD+ levels decline with age in some tissues, researchers study whether raising NMN availability can influence NAD+ metabolism.
No. Human evidence is limited, and no regulatory agency has approved NMN for treating or preventing aging. Some trials measure NAD+ metabolites or metabolic markers, but their results do not establish a clinical benefit. Larger, longer studies with standardized endpoints are needed.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It occurs naturally in cells and is also produced commercially as a supplement ingredient.